•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Maptelligent, Inc., is Pleased to Announce it has Entered Into an Agreement With Axim Geospatial
Maptelligent is Pleased to Announce Its New Strategic Focus, Implementing the Latest in Location Intelligence Making Indoor Maps More Intelligent
Maptelligent, Inc., is Pleased to Announce a Partnership with Michael Quan with the Interactive Tactical Group
NSION Technologies & Maptelligent Strategic Partnership
Maptelligent, Inc., is Pleased to Announce Its New Management Services Agreement With Mr. Christopher Oudegeest, the Founder of Asbuilt Conditions
Maptelligent, Inc. is Pleased to Announce Its New Strategic Partnership With the Award-winning Kant Consulting Group
Maptelligent, Inc. Announces Mr. Joel Rothschild as Chief Technical Officer
Maptelligent, Inc., Rebranding Efforts With the Launch of a New Website
Maptelligent, Inc., Solution Innovation
Maptelligent, Inc., Executes an Agreement With GeoComm, Inc.
UPDATE -- Maptelligent, Inc. Announces Mr. Eric Kant of Kant Consulting Group, LLC as a Consultant